Skip to main content
. Author manuscript; available in PMC: 2017 Jan 8.
Published in final edited form as: ACS Infect Dis. 2015 Oct 17;2(1):82–92. doi: 10.1021/acsinfecdis.5b00108

Figure 3.

Figure 3

Predicted trapping potency and protection by 5 and 10 µg/mL NIH45-46 with varying affinity to mucins as characterized by α: (A) predicted fraction of HIV load initially in semen that can diffuse across CVM containing NIH45-46 over the first 2 h post-deposition; (B) average number of NIH45-46 bound to HIV arriving at the vaginal epithelium (values <1 represent HIV virions that arrive at the vaginal epithelium without any bound NIH45-46); (C, D) extent of NIH45-46-mediated protection, as quantified by infectivity relative to (C) no NIH45-46 present in CVM or (D) the same amount of NIH45-46 present but without any affinity to mucins.